Nature Communications 에 기재된 'Antibody targeting intracellular oncogenic Ras mutants exerts
anti-tumor effects systemic administration.' 논문이 F1000Prime 에 Article Recommendations 로
While antibody administration has become entrenched as a viable therapeutic option,
especially for oncologic applications, targets have been limited to extracellular components due to
inability to traverse the plasma membrane. Shin et al. describe a novel methodology that targets
monoclonal antibodies to a cytoplasmic compartment by the addition of a "homing peptide" that
binds to a tumor-associated integrin allowing for internalization with eventual endosomal escape
into the cytoplasm demonstrating activity against a Ras mutant, providing proof of principle for this
concept. While these "internalizing" MAbs (iMAbs) currently suffer from poor endosomal escape
and a short half-life in circulation, these deficiencies appear more as technical concerns,
rather than fundamental impediments. The ability to selectively direct MAbs to cytoplasmic targets
could herald a new technical approach to address a wide range of medical conditions.
Recommended by Michael Kurilla and Randall Kincaid.